168 related articles for article (PubMed ID: 18036248)
21. Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF.
Hemmati PG; Normand G; Gillissen B; Wendt J; Dörken B; Daniel PT
Oncogene; 2008 Dec; 27(53):6707-19. PubMed ID: 18806827
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of p16INK4A and p14ARF in haematological malignancies.
Lee YK; Park JY; Kang HJ; Cho HC
Clin Lab Haematol; 2003 Aug; 25(4):233-7. PubMed ID: 12890162
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
24. [Effect of 14-3-3sigma on transcriptional activity of p73 gene].
Sang MX; Geng CZ; Shan BE
Ai Zheng; 2007 May; 26(5):489-93. PubMed ID: 17672938
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.
Dote H; Cerna D; Burgan WE; Carter DJ; Cerra MA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2005 Jun; 11(12):4571-9. PubMed ID: 15958643
[TBL] [Abstract][Full Text] [Related]
26. Methylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation of the p16 gene in colorectal cancers as analyzed by bisulfite PCR-SSCP.
Nomoto K; Maekawa M; Sugano K; Ushiama M; Fukayama N; Fujita S; Kakizoe T
Jpn J Clin Oncol; 2002 Jan; 32(1):3-8. PubMed ID: 11932355
[TBL] [Abstract][Full Text] [Related]
27. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.
Han B; Xie H; Chen Q; Zhang JT
Mol Cancer Ther; 2006 Apr; 5(4):903-12. PubMed ID: 16648560
[TBL] [Abstract][Full Text] [Related]
28. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma.
Shiba-Ishii A; Noguchi M
Am J Pathol; 2012 Apr; 180(4):1653-62. PubMed ID: 22310466
[TBL] [Abstract][Full Text] [Related]
29. 14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation.
Zhang Y; Karas M; Zhao H; Yakar S; LeRoith D
J Biol Chem; 2004 Aug; 279(33):34353-60. PubMed ID: 15187095
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor gene 14-3-3sigma is down-regulated whereas the proto-oncogene translation elongation factor 1delta is up-regulated in non-small cell lung cancers as identified by proteomic profiling.
Liu Y; Chen Q; Zhang JT
J Proteome Res; 2004; 3(4):728-35. PubMed ID: 15359725
[TBL] [Abstract][Full Text] [Related]
31. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front.
Ide M; Nakajima T; Asao T; Kuwano H
Cancer Lett; 2004 Apr; 207(2):241-9. PubMed ID: 15072834
[TBL] [Abstract][Full Text] [Related]
33. Expression of p16INK4A and p14ARF in hematological malignancies.
Taniguchi T; Chikatsu N; Takahashi S; Fujita A; Uchimaru K; Asano S; Fujita T; Motokura T
Leukemia; 1999 Nov; 13(11):1760-9. PubMed ID: 10557050
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
36. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies.
Suyama T; Ohashi H; Nagai H; Hatano S; Asano H; Murate T; Saito H; Kinoshita T
Leuk Res; 2002 Dec; 26(12):1113-8. PubMed ID: 12443884
[TBL] [Abstract][Full Text] [Related]
37. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression.
Hermeking H; Lengauer C; Polyak K; He TC; Zhang L; Thiagalingam S; Kinzler KW; Vogelstein B
Mol Cell; 1997 Dec; 1(1):3-11. PubMed ID: 9659898
[TBL] [Abstract][Full Text] [Related]
38. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.
Su CH; Zhao R; Zhang F; Qu C; Chen B; Feng YH; Phan L; Chen J; Wang H; Wang H; Yeung SC; Lee MH
Cancer Res; 2011 Feb; 71(3):884-94. PubMed ID: 21135113
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Jing F; Zhang J; Tao J; Zhou Y; Jun L; Tang X; Wang Y; Hai H
Onkologie; 2007 Feb; 30(1-2):14-9. PubMed ID: 17264521
[TBL] [Abstract][Full Text] [Related]
40. Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts.
Ghahary A; Marcoux Y; Karimi-Busheri F; Li Y; Tredget EE; Kilani RT; Lam E; Weinfeld M
J Invest Dermatol; 2005 Jan; 124(1):170-7. PubMed ID: 15654971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
